Comparison of surgical results of D2 versus D3 gastrectomy (para-aortic lymph node dissection) for advanced gastric carcinoma: A multi-institutional study

被引:63
作者
Kunisaki, C
Akiyama, H
Nomura, M
Matsuda, G
Otsuka, Y
Ono, H
Nagahori, Y
Hosoi, H
Takahashi, M
Kito, F
Shimada, H
机构
[1] Yokohama City Univ, Grad Sch Med, Dept Surg Gastroenterol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan
[2] Yokosuka Kyosai Hosp, Dept Surg, Yokosuka, Kanagawa 2380011, Japan
[3] Yokohama Municipal Hosp, Dept Surg, Hodogaya Ku, Yokohama, Kanagawa 2400062, Japan
关键词
advanced gastric cancer; D2; gastrectomy; D3; para-aortic lymph node dissection;
D O I
10.1245/ASO.2006.07.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Curative gastrectomy is a promising approach for the treatment of gastric cancer; however, the optimal extent of lymph node dissection for advanced cancer remains controversial. The aim of this multi-institutional study was to evaluate the feasibility of D3 gastrectomy (para-aortic lymph node dissection) for advanced gastric cancer. The surgical results of D2 and D3 gastrectomy (para-aortic lymph node dissection) were retrospectively compared. A series of 580 advanced gastric cancer patients were registered between 1992 and 2000. Of these, 430 underwent D2 gastrectomy and 150 underwent D3 gastrectomy. Survival time, prognostic factors, postoperative morbidity/mortality, and pattern of recurrence were compared. There was no significant difference in survival time between D2 and D3 patients. However, the survival times of D3 patients with tumor diameters measuring 50 to 100 mm or with pN1 disease were significantly longer than those of the corresponding D2 patients. Analysis of the survival of patients with tumor diameters measuring 50 to 100 mm revealed that D3 gastrectomy conferred a survival advantage only to patients with pN2 disease. The incidence of lymphatic recurrence was lower in D3 patients with 50- to 100-mm tumors than in the corresponding D2 patients. D3 gastrectomy might be beneficial in patients with advanced pN2 gastric cancer within the group with tumors measuring 50 to 100 mm. A randomized controlled trial of patients with 50- to 100-mm tumors should be performed to test the validity of this preliminary result.
引用
收藏
页码:659 / 667
页数:9
相关论文
共 16 条
[1]  
Baba M, 2000, HEPATO-GASTROENTEROL, V47, P893
[2]   RANDOMIZED COMPARISON OF MORBIDITY AFTER D1 AND D2 DISSECTION FOR GASTRIC-CANCER IN 996 DUTCH PATIENTS [J].
BONENKAMP, JJ ;
SONGUN, I ;
HERMANS, J ;
SASAKO, M ;
WELVAART, K ;
PLUKKER, JTM ;
VANELK, P ;
OBERTOP, H ;
GOUMA, DJ ;
TAAT, CW ;
VANLANSCHOT, J ;
MEYER, S ;
DEGRAAF, PW ;
VONMEYENFELDT, MF ;
TILANUS, H ;
VANDEVELDE, CJH .
LANCET, 1995, 345 (8952) :745-748
[3]   Postoperative morbidity and mortality after D-1 and D-2 resections for gastric cancer: Preliminary results of the MRC randomised controlled surgical trial [J].
Cuschieri, A ;
Fayers, P ;
Fielding, J ;
Craven, J ;
Bancewicz, J ;
Joypaul, V ;
Cook, P .
LANCET, 1996, 347 (9007) :995-999
[4]   State of the art in the treatment of gastric cancer: from the 71st Japanese Gastric Cancer Congress [J].
Masashi Fujii ;
Juei Sasaki ;
Toshifusa Nakajima .
Gastric Cancer, 1999, 2 (3) :151-157
[5]  
Isozaki H, 1999, HEPATO-GASTROENTEROL, V46, P549
[6]  
*JAP GASTR CANC AS, 1998, GASTRIC CANCER, V1, P8
[7]  
KITAMURA M, 1991, JPN J GASTROENTEROL, V24, P1905
[8]  
Kunisaki C, 2000, HEPATO-GASTROENTEROL, V47, P586
[9]  
Kunisaki C, 1999, HEPATO-GASTROENTEROL, V46, P2635
[10]  
Kunisaki C, 2003, ANTICANCER RES, V23, P4181